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Ewing sarcoma breakpoint region 1 (EWSR1) fusion with Friend leukemia integration 1 transcription
factor (FLI1) induced by a translocation of chromosome 11 with 22 contributes to Ewing sarcoma de-
velopment. To date, the precise molecular mechanisms about EWSR1/FLI1 involving in Ewing sarcoma
development remains to be deﬁned. This study explored the potential critical gene targets of EWSR1/FLI1
knockdown in Ewing sarcoma cells on the gene expression proﬁle based on online dataset, performed
Limma algorithm for differentially expressed genes identiﬁcation, constructed the transcriptional factor
(TF)-gene regulatory network based on integrate transcriptional regulatory element database (TRED).
The data showed up- and down-regulation of differentially expressed genes over time and peaked at 72 h
after EWSR1/FLI1 knockdown in Ewing sarcoma cells. SMAD3 were up-regulated and FLI1, MYB, E2F1,
ETS2, WT1 were down-regulated with more than half of their targets were down-regulated after EWSR1/
FLI1 knockdown. The Gene Ontology (GO) and pathway annotation of these differentially expressed
genes showed a consistent trend in each group of samples. Totally, there were 355 differentially ex-
pressed genes occurring in all ﬁve comparison groups of different time points, in which 39 genes con-
structed a dysregulated TF-gene network in Ewing sarcoma cell line A673 after EWSR1/FLI1 knockdown.
These data demonstrated that knockdown of EWSR1/FLI1 expression led to transcriptome changes in
Ewing sarcoma cells and that Ewing sarcoma development and progression caused by altered EWSR1/
FLI1 expression may be associated with more complex transcriptome changes.
& 2016 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ewing sarcoma is a rare malignancy arising in the bone and
soft-tissue and most frequently occurs in children and adoles-
cence. Molecularly, Ewing sarcoma is characterized by a translo-
cation between chromosome 11 and 22, leading to a fusion protein
of Ewing sarcoma breakpoint region 1 (EWSR1) with Friend leu-
kemia integration 1 transcription factor (FLI1). The latter is a
transcriptional activator and responsible for up to 95% of Ewing
sarcoma [1,2], although other chromosome translocations may
also occur in Ewing sarcoma [3,4]. The wild-type EWSR1 is a
member of ten-eleven translocation methylcytosine dioxygenase
gene family and could interact with the general transcriptional
components, like RNA polymerase II enzyme and TFIID complex to
regulate gene expression [5,6]. FLI1 is a member of the ETS tran-
scription factor family and functions as an oncogene to induce cell
proliferation [7]. The EWSR1/FLI1 fusion is critical for Ewingis an open access article under the
982150@qq.com (B. Wang),sarcoma tumorigenesis. For example, cells expressing EWSR1/FLI1
fusion protein can form tumors after transplanting into im-
munodeﬁcient mice [8,9], whereas cells expressing EWSR1 or FLI1
mutated protein lose the ability to form tumors in nude mice [10].
The EWSR1/FLI1 fusion protein is also important for cell growth
regulation and gene expressions in other cell lines, including CTR
rhabdomyosarcoma cells or RAT-1 ﬁbroblasts [11,12]. However, to
date, the precise molecular mechanisms about EWSR1/FLI1 fusion
protein involving in Ewing sarcoma development remains to be
deﬁned; for example, how the EWSR1/FLI1 fusion protein inter-
rupt normal cell cycle and why the EWSR1/FLI1 fusion protein only
causes Ewing sarcoma or related tumors.
To this end, we proposed this study by analyzing the whole
transcriptome after knockdown of EWSR1/FLI1 expression in Ew-
ing sarcoma cell line A673. As we know, transcriptome instability
always associated with cancer development [13], which should
also be in Ewing sarcoma. Some key transcription factors (TF) may
function as a tumor promoter or inhibitor in cells to regulate ex-
pression of their target genes. Thus, to better understand the
transcriptional status affected by EWSR1/FLI1 protein in Ewing
sarcoma, we ﬁrst retrieved datasets from online database [14] and
then analyze the data of transcriptome changes in Ewing sarcomaCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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EWSR1/FLI1 and identifying the key TF and target genes. This
study expects to provide insightful information regarding tran-
scriptome alteration caused by EWSR1/FLI1 fusion protein and to
identify the key TFs and targeting genes for future development of
novel strategies in control of Ewing sarcoma.Fig. 1. Differentially expressed genes after EWSR1/FLI1 knockdown in Ewing sar-
coma cells. The gene expression datasets GSE27524 were downloaded from GEO
Datasets of NCBI (http://www.ncbi.nlm.nih.gov/gds/). The datasets GSE27524
contained a cDNA microarray analysis of A673 in Ewing sarcoma cell line after
inducible EWSR1/FLI1 knockdown with up to 96 h data [14]. We performed the
limma algorithm in R/Bioconductor for genes with a p-value o0.05 and fold
change 42 to considered as DEGs compared to the 0 h control.2. Materials and methods
2.1. Retrieval of gene expression dataset from online database
In this study, we ﬁrst downloaded the gene expression data
series GSE27524 from GEO Datasets of NCBI (http://www.ncbi.
nlm.nih.gov/gds/). The project GSE27524 provided a systematical
analysis of gene expression using a cDNA microarray of A673
Ewing sarcoma cell line after inducible EWSR1/FLI1 knockdown
with up to 96 h data [14]. The raw data GSE27524 were obtained
from HG-U133A_2 platform (Affymetrix Human Genome U133A
2.0 Array) and all the microarrays raw data (.CEL) from this project
were included for this study, which contains 4 samples of 0 h,
3 samples of 18 h, 3 samples of 36 h, 2 samples of 54 h, 2 samples
of 72 h, 2 samples of 96 h after EWSR1/FLI1 knockdown in A673
Ewing sarcoma cell line. After downloading the raw data, we ap-
plied R statistics analysis language and software for data proces-
sing. First we have to check the quality of the data, results showed
a qualiﬁed quality and reasonable sample cluster of all the 16
microarray raw datasets (Supplementary Fig. 1).
2.2. Proﬁling of differentially expressed genes (DEGs) in Ewing sar-
coma after EWSR1/FLI1 knockdown
To identify DEGs in Ewing sarcoma after EWSR1/FLI1 knock-
down, we utilized the limma algorithm package in R/Bioconductor
to identify differentially expressed genes between two groups at a
time [15,16]. The dataset on 0 h was used as the control group and
we compared the other ﬁve time points after EWSR1/FLI1 knock-
down to the 0 h control. Genes with p-value o0.05, false dis-
covery rata (FDR)o0.05 and fold change (FC)42 between two
groups were considered as the DEGs.
2.3. Analysis of the TF-gene regulatory network based on gene ex-
pression and transcriptional regulatory element database (TRED)
The TRED (http://rulai.cshl.edu/TRED) provides an accurate and
comprehensive knowledge involves transcriptional regulatory
elements [16,17]. Thus, we ﬁrst obtained all the transcription
factor-gene regulation modes on 36 cancer-related TF families
from TRED, then constructed the dysregulated TF-genes regulatory
network by integrating DEGs with transcriptional regulation
modes. The Cytoscape software was utilized to visualize such
regulatory networks [16,18]. For example, triangles in the network
are TFs (orange for up-regulated, yellow for down-regulated),
circles in the network are target genes (red for up-regulated and
green for down-regulated) in A673 Ewing sarcoma cells after
EWSR1/FLI1 knockdown. Relationship between TFs and their tar-
gets were interacted by arrows, direction of the arrow was from
the Source (TFs) to the Target (genes).
2.4. Functional annotations of DEGs
To explore the function of selected DEGs, we applied the online
analytical tools [Database for Annotation, Visualization and In-
tegrated Discovery (DAVID)] to obtain the Gene Ontology (GO) and
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway en-
richment [19]. We ﬁrst uploaded the selected DEGs(OFFICIAL_GENE_SYMBOL) list into DAVID tools for functional an-
notation, and then collected data information from “GENE_ON-
TOLOGY” [including GO_BP (Gene Ontology_Biological Process),
GO_CC (Gene Ontology_Cellular Component) and GO_MF (Gene
Ontology_Molecular Function)] and “KEGG_PATHWAY” for GO and
pathway analysis. GO and KEGG terms with Po0.05 were selected
as statistically signiﬁcant enriched.3. Results
3.1. Identiﬁcation of differentially expressed genes (DEGs) in Ewing
sarcoma after EWSR1/FLI1 knockdown
In this study, we ﬁrst identiﬁed DEGs in Ewing sarcoma after
EWSR1/FLI1 knockdown by using the downloaded gene expres-
sion datasets GSE27524 from GEO Datasets of NCBI (http://www.
ncbi.nlm.nih.gov/gds/). The datasets GSE27524 contained a cDNA
microarray analysis of A673 in Ewing sarcoma cell line after in-
ducible EWSR1/FLI1 knockdown with up to 96 h data [14]. We
applied the limma algorithm in R/Bioconductor for genes with a p-
valueo0.05 and fold change 42 to considered as DEGs compared
to the 0 h control. Fig. 1 shows the number of DEGs in the ﬁve
comparison groups, detail informations were summarized in
Supplementary Table 1. Results indicated that fewer DEGs oc-
curred in 18 h time point vs. 0 h time point and the DEGs reached
the maximal numbers in 72 h time point after EWSR1/FLI1
knockdown (Fig. 1).
3.2. Functional annotations of selected DEGs
We then uploaded these DEGs in all ﬁve groups to the DAVID
tool for functional annotation. Fig. 2 and Supplementar-
y_GO_KEGG showed the number and detailed information of GO-
BP, GO-CC, GO-MF and KEGG pathway terms that DEGs involved in
each group. We found that the changes of GO and KEGG terms
showed almost the consistent trend with DEGs changes in each
time point, that peaked in 72 h. We then focused on the DEGs that
aberrantly expressed in all ﬁve groups to explore the biology
function changes in Ewing sarcoma cells after EWSR1/FLI1
knockdown. A total of 355 genes were obtained, including 172
upregulated DEGs and 180 downregulated DEGs in all of these ﬁve
comparison groups, while three DEGs showed a different
Fig. 2. Summary of GO and KEGG terms of these DEGs among these ﬁve time-points vs. oh control in Ewing sarcoma cells after EWSR1/FLI1 knockdown. These DEGs were
subjected to the Gene Ontology and KEGG pathway analysis.
Table 1.
KEGG pathway terms of up- and down-regulated genes in Ewing sarcoma cells after EWSR1/FLI1 knockdown.
KEGG term P Fold enrichment Gene names
Upregulated genes ECM-receptor interaction o0.01 6.52 ITGA6, COL6A3, COL3A1, COL1A2, COL6A1, ITGA4, FN1
Focal adhesion o0.01 3.89 EGFR, ITGA6, COL6A3, COL3A1, COL1A2, PDGFRA, COL6A1, ITGA4, MYLK, FN1
Axon guidance o0.01 4.85 SEMA6A, PLXNC1, UNC5B, GNAI1, L1CAM, SEMA3A, UNC5C, CXCL12
Pathways in cancer 0.02 2.39 EGFR, PLD1, CBLB, PTGS2, ITGA6, PDGFRA, SMAD3, FOXO1, TCF7L2, FN1
Calcium signaling pathway 0.02 3.11 EGFR, ATP2B1, ATP2B4, PLCB4, PDGFRA, ITPR1, MYLK
Prostate cancer 0.03 4.39 EGFR, PDGFRA, CREB3L1, FOXO1, TCF7L2
Gap junction 0.03 4.39 EGFR, PLCB4, GNAI1, PDGFRA, ITPR1
Downregulated genes Cell cycle o0.01 6.21 E2F1, CDC6, CCND1, CDC45, E2F5, SKP2, PKMYT1, MCM4, CDC25A
Purine metabolism 0.03 3.38 POLR3G, POLR3K, RRM2, PDE4A, PDE3B, GART
P: modiﬁed ﬁsher exact p-value. The smaller, the more enriched.
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ble 2). The biological function and pathway annotation using the
DAVID tool indicated that the upregulated DEGs involved in 102
GO-BP, 16 GO-CC, 23 GO-MF and 7 KEGG terms, the downregulated
DEGs involved in 42 GO-BP, 21 GO-CC, 9 GO-MF and 2 KEGG terms.
Tabless 1 and 2 summariz the KEGG terms and top 3 signiﬁcant GO
terms (including GO-BP/CC/MF) of DEGs.
3.3. Changes in transcription factors in Ewing sarcoma cells after
EWSR1/FLI1 knockdown
To explore the transcriptome changes after EWSR1/FLI1knock-
down in Ewing sarcoma cells, we utilized the TRED database to
perform transcriptome analysis. The TRED database provides
comprehensive and accurate trans-regulatory information for
target genes of more than 140 cancer-related transcription factors(belong to 36 cancer-related TF families). Our data summarized in
Table 3 show the differentially expressed TFs in these ﬁve com-
parison groups. Besides FLI1 knockdown, other eight TFs also
showed changes in all ﬁve groups, including TFAP2B/SMAD3 up-
regulation and WT1/EGR4/ETS2/E2F1/E2F5/MYB down-regulation.
The trend of the aberrant TFs was in according to DEGs for each
comparison group and peaked in 72 h after EWSR1/FLI1 knock-
down. Furthermore, based on the trans-regulatory information
from this transcriptional regulatory element database, we further
identiﬁed the dysregulated TF-genes network involved in these
355 genes that were aberrantly expressed in all ﬁve groups. This
network containing six TFs and 33 targets that including 42 dif-
ferent regulation modes (Fig. 3A). More than half of the genes in
this network were down-regulated (including transcription factors
MYB/ETS2/FLI1/E2F1/WT1 and 18 targets) and Fig. 3B showes the
bi-clusters analysis data on these 39 genes (containing six TFs) in
Table 2.
Top 3 signiﬁcant GO of DEGs in Ewing sarcoma cells after EWSR1/FLI1 knockdown.
GO term P Fold enrichment Gene names
Upregulated genes (BP) cell morphogenesis involved in
differentiation
o0.01 6.03 L1CAM, SOX9, CXCL12, SEMA6A, UNC5B, ANK3, TGFBR3, SEMA3A, UNC5C, APBB2, NEFL, DST, GAP43, DCLK1, FN1
neuron projection morphogenesis o0.01 6.44 EGFR, L1CAM, CXCL12, GAS7, SEMA6A, UNC5B, ANK3, SEMA3A, UNC5C, APBB2, NEFL, DST, DCLK1, GAP43
cell morphogenesis o0.01 4.68 EGFR, L1CAM, SOX9, CXCL12, GAS7, SEMA6A, UNC5B, ANK3, TGFBR3, SEMA3A, UNC5C, APBB2, NEFL, DST, GAP43, DCLK1,
FN1
(CC) extracellular region part o0.01 2.32 EGFR, SPARCL1, SORL1, COL3A1, OLFML2A, NID2, CXCL12, VCAM1, DKK3, BGN, TGFBI, COL6A3, COL1A2, TGFBR3, COL6A1,
STC1, ANGPT1, MFAP4, DST, BMP5, FN1, IGFBP5, VLDLR
extracellular matrix o0.01 3.37 BGN, SPARCL1, TGFBI, COL6A3, COL3A1, COL1A2, OLFML2A, COL6A1, NID2, MFAP4, DST, FN1
extracellular matrix part o0.01 6.62 COL6A3, COL3A1, COL1A2, COL6A1, NID2, MFAP4, DST, FN1
(MF) calmodulin binding o0.01 6.52 ATP2B1, ATP2B4, CALD1, MARCKS, GEM, RGS16, ADD3, GAP43, MYLK
platelet-derived growth factor binding o0.01 36.88 COL3A1, COL1A2, PDGFRA, COL6A1
integrin binding o0.01 10.31 VCAM1, ITGA6, TGFBI, COL3A1, L1CAM, DST
Downregulated genes (BP) DNA replication o0.01 6.17 CDC6, DTL, GINS3, NASP, MCM10, MCM4, C10ORF2, CDC25A, RFC3, CDC45, DKC1, RRM2, CHAF1A
DNA metabolic process o0.01 3.74 EXO1, CDC6, XRCC3, DTL, UNG, NASP, GINS3, BRIP1, MCM10, MCM4, CDC25A, C10ORF2, RFC3, CDC45, DCLRE1A, DCLRE1B,
DKC1, RRM2, BCL11B, CHAF1A, ADRA1D
ribosome biogenesis o0.01 8.13 EXOSC9, DKC1, NOLC1, EXOSC7, NIP7, BYSL, BRIX1, RRS1, RPL5, RRP9, NOP56
(CC) intracellular organelle lumen o0.01 2.94 E2F1, GRPEL1, E2F5, PKMYT1, TIMM50, MCM10, CDC45, DKC1, DDX11, URB2, AEN, TARDBP, MYB, CDC6, EXOSC9, EXOSC7,
NIP7, BYSL, RRP9, MCM4, C10ORF2, CD3EAP, RFC3, CCND1, ALDH1B1, MYBBP1A, NUFIP1, ZBTB16, WT1, SRRT, PPAN, NUP50,
TEAD4, BRIX1, RPL5, NKX2–2, POLR3G, POLR3K, PNO1, CDC25A, IDH3A, PPIF, PLK4, NOLC1, NOP16, POP1, RRS1, NOP56,
UTP20, DDX52
nuclear lumen o0.01 3.25 E2F1, E2F5, NUFIP1, PKMYT1, TIMM50, ZBTB16, MCM10, WT1, PPAN, SRRT, CDC45, DKC1, DDX11, URB2, AEN, TARDBP, BRIX1,
NUP50, TEAD4, RPL5, MYB, MYBBP1A, POLR3G, CDC6, EXOSC9, POLR3K, EXOSC7, NIP7, BYSL, PNO1, RRP9, MCM4, CDC25A,
CD3EAP, PLK4, RFC3, CCND1, NOLC1, NOP16, POP1, RRS1, NOP56, UTP20, DDX52, NKX2–2
organelle lumen o0.01 2.89 E2F1, GRPEL1, E2F5, PKMYT1, TIMM50, MCM10, CDC45, DKC1, DDX11, URB2, AEN, TARDBP, MYB, CDC6, EXOSC9, EXOSC7,
NIP7, BYSL, RRP9, MCM4, C10ORF2, CD3EAP, RFC3, CCND1, ALDH1B1, MYBBP1A, NUFIP1, ZBTB16, WT1, SRRT, PPAN, NUP50,
TEAD4, BRIX1, RPL5, NKX2–2, POLR3G, POLR3K, PNO1, CDC25A, IDH3A, PPIF, PLK4, NOLC1, NOP16, POP1, RRS1, NOP56,
UTP20, DDX52
(MF) RNA binding o0.01 2.26 EXOSC9, PUS1, EXOSC7, NIP7, PNO1, NUFIP1, TIMM50, RRP9, NR0B1, WT1, DKC1, DDX11, TARDBP, RPL5, NOP56, AKAP1,
DDX52
structure-speciﬁc DNA binding o0.01 4.61 EXO1, ZBTB16, NR0B1, MCM4, WT1, C10ORF2, FEV
DNA helicase activity 0.01 9.55 DDX11, BRIP1, MCM4, C10ORF2
P: modiﬁed ﬁsher exact p-value. The smaller, the more enriched.
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Table 3.
Differentially expressed TFs among these ﬁve time-points vs. o h control in Ewing sarcoma cells after EWSR1/FLI1 knockdown.
Upregulated TFs Downregulated TFs
18 h TFAP2B, SMAD3, PAX6 WT1, EGR4, MYC, ETS2, E2F1, E2F5, MYB, FLI1
36 h JUNB, TFAP2A, TFAP2B, TFAP2C, ATF3, EGR2, EGR3, GLI1, PPARD, SMAD3, STAT6 BRCA1, BRCA2, E2F1, E2F3, E2F5, EGR4, ETS2, FLI1, MYB, MYBL1,
MYBL2, MYC, STAT1, WT1
53 h FOS, FOSB, JUN, JUNB, TFAP2A, TFAP2B, TFAP2C, ATF3, ATF4, ATF6, BCL3, CEBPD, CREB5, EGR1,
EGR2, EGR3, GLI3, EPAS1, MSX1, NFκB1, PPARD, RARB, SMAD3, SMAD5, STAT3, STAT6
BRCA1, BRCA2, E2F1, E2F5, EGR4, ELK4, ETS2, FLI1, MYB, MYBL1,
MYBL2, POU3F1, WT1
72 h EPAS1, TFAP2C, RARB, CEBPD, JUNB, TFAP2B, RELB, MSX2, BCL3, EGR3, SMAD5, NFκB1, SMAD3,
ELK3, SMAD7, STAT3, PPARD, EGR2, BCL6, ATF6, NFκB2, GLI3, LEF1, CREB5, STAT6, TFAP2A
PAX9, POU3F1, ELK4, PAX6, EGR4, WT1, ETS2, MYBL1, E2F5,
BRCA1, FLI1, MYB, BRCA2, E2F1, MYBL2
96 h EPAS1, TFAP2C, RARB, TFAP2B, SMAD3, JUNB, BCL3, CEBPD, SMAD7, ELK3, BCL6, PPARD WT1, BRCA1, POU3F1, SMAD6, ELK4, MYC, EGR4, PAX9, BRCA2,
MYBL2, E2F1, MYB, ETS2, E2F5, FLI1
The underlines were differentially expressed TFs that occurred in all ﬁve time-points.
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Translocation of chromosome 11 with 22 causes Ewing sarcoma
breakpoint region 1 (EWSR1) fusion with Friend leukemia in-
tegration 1 transcription factor (FLI1) and in turn contributes to up
to 95% of Ewing sarcoma. However, to date, the underlying mo-
lecular mechanisms responsible for EWSR1/FLI1 expression-in-
duced Ewing sarcoma development remain to be deﬁned. Thus,
the current study explored the transcriptome changes after
EWSR1/FLI1 knockdown in Ewing sarcoma cells. We utilized a
combination of gene expression array data to perform the limma
algorithm in R/Bioconductor to obtain DEGs and then DAVID an-
notation and transcriptional regulatory element database to
identify transcriptome changes after EWSR1/FLI1 knockdown in
Ewing sarcoma cells. After assessed the aberrantly expressed
genes at different time points after EWSR1/FLI1 knockdown, we
found an increasing DEGs over time and peaked in 72 h, which is
almost consistent with GO-BP/CC/MF and KEGG pathwayFig. 3. Construction of the TF-gene regulatory network and bi-clusters analysis of the
(orange for up-regulated, yellow for down-regulated); circles are target genes (red for
arrows is from the Source (TFs) to the Target. (B) The Bi-cluster analysis of all DEGs in th
row represents a gene and each column represents a sample.annotation changes over time, suggesting that EWSR1/FLI1 ex-
pression altered the transcriptome instability and subsequent
biological alterations in Ewing sarcoma.
Speciﬁcally, we found 355 DEGs in all of the ﬁve comparison
groups vs. the 0 h control after EWSR1/FLI1 knockdown, although
the number of DEGs in each group was different. Expression pat-
terns of these 355 DEGs (except three genes) were almost the
same in these ﬁve comparison groups, including 172 upregulated
DEGs and 180 downregulated DEGs, which involved in nine sig-
niﬁcant gene pathways. For example, the ECM-receptor interac-
tions and the focal adhesion are the key pathways involved in
cancer metastasis [20]. The EWS/FLI oncogene was reported to
drive changes in cellular morphology, adhesion and migration of
Ewing sarcoma. Moreover, these DEGs were also enriched in the
axon guidance and calcium signaling pathways. No direct asso-
ciation of axon guidance pathway with Ewing sarcoma has ever
been reported yet. In a research of osteosarcoma, the differentially
expressed genes in metastatic osteosarcoma was enriched in the
axon guidance and focal adhesion according to biological process.
The most signiﬁcant gene pathway for the downregulated DEGs
involved in regulation of the cell cycle. Researches had showedse DEGs. (A) The regulation information are derived from TRED. Triangles are TFs
up-regulated genes and green circles for down-regulated genes). The direction of
e TF-gene regulatory network based on gene expression value in each sample. Each
J. Wang et al. / Journal of Bone Oncology 5 (2016) 153–158158that genes transcriptionally deregulated by EWSR1/FLI1 have the
potential to contribute to malignant transformation, such as cell
cycle regulators cyclinD1, indicated that EWSR1/FLI1 knockdown
may partly inhibit the cell cycle progression of Ewing sarcoma
[21]. In addition to cancer-related gene pathways, the down-
regulated DEGs were also enriched in purine metabolism, revealed
that EWSR1/FLI1 may involved in Ewing sarcoma tumorigenesis
and progression by upregulation of purine metabolism for DNA
synthesis and cell proliferation. These data indicate that EWSR1/
FLI1 fusion protein alters cell cycle and upregulates purine and
pyrimidine metabolism. Future study will focus on how and
whether to manipulate these gene pathways for reverse Ewing
sarcoma tumorigenesis.
Furthermore, our current study also explored the transcriptome
changes caused by EWSR1/FLI1 knockdown in Ewing sarcoma and
found that there were nine transcription factors dysregulated in all
of these ﬁve comparison groups compared to control after EWSR1/
FLI1 knockdown. Six of these nine pathways could construct a TF-
gene regulatory network. As the only upregulated TF in this net-
work, expression of SMAD3 and three of its targets were increased
after EWSR1/FLI1 knockdown. The other ﬁve TFs and more than
half of their targets were down-expressed in this network. For
example, as an oncoprotein, MYB was downregulated and in turn
regulated the most targets in this TF-gene network after EWSR1/
FLI1 knockdown in Ewing sarcoma cells. A previous study de-
monstrated that B-MYB, a member of MYB family, was stabilized
by the proteasome inhibitor in Ewing sarcoma cells and B-MYB
accumulation could promote tumor progression [22]. Recently,
EWS-FLI1 fusion protein showed to function as an E2F switch to
drive target gene expression, activation of E2F3 protein cooperated
with ETS on the targeting gene promoters could consequently lead
to an aberrant cell cycle activation [23]. In addition, WT1 protein is
able to regulate target gene transcription and mRNA splicing to
contribute to angiogenesis in Ewing sarcoma by increase in ex-
pression of pro-angiogenic molecules (VEGF, MMP9, Ang-1 and
Tie-2) [24].
In conclusion, the current study explored altered transcriptome
after EWSR1/FLI1 knockdown in Ewing sarcoma cells and identi-
ﬁed a dysregulated TF-gene regulatory network. However, our
current study is just proof-of-principle and further researches are
needed to experimentally manipulate the gene pathways after
EWSR1/FLI1 knockdown or knock-in in Ewing sarcoma cells to
conﬁrm their role in mediation of EWSR1/FLI1 fusion protein in
development of Ewing sarcoma.Conﬂict of interest statement
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